Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Research Nurses Team, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Cancer Invest. 2021 Jan;39(1):9-14. doi: 10.1080/07357907.2020.1844893. Epub 2020 Nov 6.
The outbreak of COVID-19 pandemia is a major health worldwide concern. Patients with cancer might have a worse outcome, because of the immunosuppression determined by the tumor itself and anti-cancer treatments, including chemotherapy and radiotherapy. The impact and course of viral infection in patients receiving immunotherapy remains unknown. We report the case of a patient with metastatic melanoma, long responder to anti PD-1 blockade who got infected with Sars CoV-2, recovering without sequelae. A critical review of literature was performed. Limited data available in literature support the possibility to continue the immunotherapy in patients with cancer under control.
COVID-19 大流行的爆发是全球主要的健康关注点。由于肿瘤本身和包括化疗和放疗在内的抗癌治疗引起的免疫抑制，癌症患者的预后可能更差。接受免疫治疗的患者中病毒感染的影响和过程尚不清楚。我们报告了一例转移性黑色素瘤患者的病例，该患者对 PD-1 阻断剂有长期反应，感染了 SARS-CoV-2，但没有后遗症。我们进行了文献的批判性回顾。文献中有限的数据支持在癌症得到控制的情况下继续为患者进行免疫治疗的可能性。
